| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5845423 | Progress in Neuro-Psychopharmacology and Biological Psychiatry | 2012 | 8 Pages |
Abstract
⺠5-HTTLPR genetic test can guide antidepressant choice with small clinical benefits. ⺠5-HTTLPR test cost is the main determinant in economic evaluation. ⺠Genetic test use might be cost-effective in high-income countries. ⺠At present genetic test is not cost-effective in middle-income countries.
Keywords
specific serotonin reuptake inhibitorCost-effectiveness acceptability curveCEACCUAICERHRQOLPPPTCAMDDSNRIMajor depressive disorderDepressionChoiceCost-utility analysisGross domestic productGDPPharmacoeconomicsAntidepressantsTricyclic antidepressantWorld Health OrganizationCost–benefitPharmacogeneticsserotonin-norepinephrine reuptake inhibitorSSRIIncremental cost-effectiveness ratioWHOHealth-related quality of life
Related Topics
Life Sciences
Neuroscience
Biological Psychiatry
Authors
Paolo Olgiati, Emanuele Bajo, Marco Bigelli, Diana De Ronchi, Alessandro Serretti,